© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Recommendations for identifying neuromyelitis optica spectrum disorders in the community and using immunosuppressive therapy to help prevent acute attacks.
September 21st 2021
Mayo Clinic’s Brian G. Weinshenker, MD, compares multiple sclerosis with neuromyelitis optica spectrum disorders (NMOSD) and explains why community neurologists need to receive more education on NMOSD risk factors and symptoms.
Doug and Kim, patients with neuromyelitis optica spectrum disorders, describe the types of symptoms that prompted each of them to seek an evaluation by a neurologist for an eventual diagnosis of a neuromyelitis optica spectrum disorder.
September 28th 2021
Jacinta M. Behne, MA, describes how the Guthy-Jackson Charitable Foundation supports patients with neuromyelitis optica spectrum disorders.
Types of testing that can help neurologists distinguish between acute attacks of neuromyelitis optica spectrum disorders (NMOSD) and multiple sclerosis, as well as therapies that can be used to help manage patients with NMOSD.
October 5th 2021
An overview of newer preventive therapies approved for acute attacks of neuromyelitis optica spectrum disorders, and variables that impact treatment selection.
What to know about treating patients with neuromyelitis optica spectrum disorders throughout the COVID-19 pandemic.
October 12th 2021
Kim, a patient with neuromyelitis optica, describes what it has been like receiving rituximab infusions as preventive therapy, and shares advice for others who are about to embark on a similar treatment journey.
Neuromyelitis optica patient Doug highlights the types of treatments he has received since his diagnosis and provides suggestions to patients on navigating therapy, especially during the COVID-19 pandemic.
October 19th 2021
Jacinta M. Behne, MA, of the Guthy-Jackson Charitable Foundation, reacts to the types of research programs the organization has been involved in, regarding better treatments for patients with neuromyelitis optica spectrum disorders.
Patients with neuromyelitis optica spectrum disorders highlight the types of resources and support that have helped them manage their neurological condition.